Creative Medical Technology (NASDAQ:CELZ) and Anika Therapeutics (NASDAQ:ANIK) Head-To-Head Review

Creative Medical Technology (NASDAQ:CELZ) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional & Insider Ownership

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by insiders. Comparatively, 12.1% of Anika Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Creative Medical Technology has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500.

Valuation and Earnings

This table compares Creative Medical Technology and Anika Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$3,000.00	1,366.95	-$5.99 million	($1.99)	-0.31
Anika Therapeutics	$112.82 million	1.73	-$10.88 million	($0.27)	-53.89

Creative Medical Technology has higher earnings, but lower revenue than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Creative Medical Technology and Anika Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-86.52%	-81.96%
Anika Therapeutics	-3.14%	0.20%	0.15%

Analyst Recommendations

This is a summary of recent ratings and price targets for Creative Medical Technology and Anika Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1	0	1	0	2.00
Anika Therapeutics	1	1	2	0	2.25

Anika Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 51.20%. Given Anika Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Anika Therapeutics is more favorable than Creative Medical Technology.

Summary

Anika Therapeutics beats Creative Medical Technology on 9 of the 14 factors compared between the two stocks.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

About Anika Therapeutics

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.